Citi Maintains a 'Hold' on Somanetics Corp (SMTS); Walk Off – Inline Results Ahead of COV Acquisition
SMTS Hot Sheet
Rating Summary:0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 7 | New: 15
Citi maintains a 'Hold' on Somanetics Corp (Nasdaq: SMTS), raises price target from $21 to $25.
Citi analyst says, "SMTS reported solid results last night and cancelled its previously scheduled conference call for this morning in light of its pending acquisition by Covidien (NYSE: COV) (Buy-rated). We continue to see little risk to the deal closing with no other obvious suitors or significant regulatory issues...Consistent with our view that the COV will acquire outstanding shares for $25 in cash by the 7/31/2010 targeted closing date, we are increasing our target to the agreed upon price. Immaterial estimate changes reflect results of the recent quarter."
To see all the upgrades/downgrades on shares of SMTS, visit our Analyst Ratings page.
Somanetics Corporation develops, manufactures and markets the INVOS System, a non-invasive patient monitoring system that provides accurate, real-time blood oxygen measurements in the brain and elsewhere in the body in tissues beneath the sensor in patients greater than 2.5 kilograms and continuously measures changes in blood oxygen levels for individuals of any weight.
Citi analyst says, "SMTS reported solid results last night and cancelled its previously scheduled conference call for this morning in light of its pending acquisition by Covidien (NYSE: COV) (Buy-rated). We continue to see little risk to the deal closing with no other obvious suitors or significant regulatory issues...Consistent with our view that the COV will acquire outstanding shares for $25 in cash by the 7/31/2010 targeted closing date, we are increasing our target to the agreed upon price. Immaterial estimate changes reflect results of the recent quarter."
To see all the upgrades/downgrades on shares of SMTS, visit our Analyst Ratings page.
Somanetics Corporation develops, manufactures and markets the INVOS System, a non-invasive patient monitoring system that provides accurate, real-time blood oxygen measurements in the brain and elsewhere in the body in tissues beneath the sensor in patients greater than 2.5 kilograms and continuously measures changes in blood oxygen levels for individuals of any weight.
You May Also Be Interested In
- UBS Maintains a 'Buy' on JPMorgan (JPM); Patient Investors Will Be Rewarded
- Barclays Maintains an 'Equalweight' on Apollo Commercial Real Estate Finance (ARI); Effectively Using Capital, But Shares Trading In-line Vs. Peers
- Guggenheim Initiates Coverage on Several Oil & Gas Drilling & Exploration Stocks; Upgrades DO & ESV, Lowers RDC
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
